Pharmacological and respiratory treatment in three patients with Spinal Muscular Atrophy type 1
PDF (Español (España))
PDF

Keywords

Werdnig-Hoffman Disease
Noninvasive Ventilation
Spinal Muscular Atrophy
Nusinersen

How to Cite

1.
Villamil-Osorio M, Bobadilla-Quesada EJ, Bolaños C, Valencia D, Ladino Y. Pharmacological and respiratory treatment in three patients with Spinal Muscular Atrophy type 1. Andes pediatr [Internet]. 2025 Jun. 25 [cited 2025 Oct. 22];96(3):402-9. Available from: https://andespediatrica.cl/index.php/rchped/article/view/5513

Cited by


Abstract

Spinal muscular atrophy type 1 (SMA 1) is a progressive neuromuscular disease with high morbidity and mortality, especially due to respiratory and nutritional complications.

Objective: To present 3 patients who managed to diverge from the natural history described for this disease due to the implementation of standards of care and disease-modifying therapies.

Clinical Case: We report three female patients with SMA 1 from the Fundación Hospital Pediátrico la Misericordia (HOMI), Colombia, with diagnosis and treatment before 6 months of age. Two of them managed to overcome respiratory failure and all 3 have been maintained without invasive respiratory support and with oral feeding, without gastrostomy.

Conclusions: Pediatric patients with SMA 1 have a serious disease that leads to respiratory failure and a high probability of early death. The implementation of multidisciplinary management strategies allows for preserving respiratory function, initiating specific disease-modifying therapies, improving their survival, and decreasing associated morbidity. 

https://doi.org/10.32641/andespediatr.v96i3.5513
PDF (Español (España))
PDF
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2025 Revista Chilena de Pediatría